Early- vs late-start levodopa relieved symptoms but did not affect disease progression in Parkinson disease
- PMID: 31108518
- DOI: 10.7326/ACPJ201905210-056
Early- vs late-start levodopa relieved symptoms but did not affect disease progression in Parkinson disease
Comment on
-
Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.N Engl J Med. 2019 Jan 24;380(4):315-324. doi: 10.1056/NEJMoa1809983. N Engl J Med. 2019. PMID: 30673543 Clinical Trial.
Similar articles
-
Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.N Engl J Med. 2019 Jan 24;380(4):315-324. doi: 10.1056/NEJMoa1809983. N Engl J Med. 2019. PMID: 30673543 Clinical Trial.
-
Selegiline slows the progression of the symptoms of Parkinson disease.Neurology. 2006 Apr 25;66(8):1200-6. doi: 10.1212/01.wnl.0000204007.46190.54. Epub 2006 Mar 15. Neurology. 2006. PMID: 16540603 Clinical Trial.
-
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.JAMA. 2002 Apr 3;287(13):1653-61. doi: 10.1001/jama.287.13.1653. JAMA. 2002. PMID: 11926889 Clinical Trial.
-
Parkinson disease: managing a complex, progressive disease at all stages.Cleve Clin J Med. 2007 May;74(5):313-4, 317-8, 320-2 passim. doi: 10.3949/ccjm.74.5.313. Cleve Clin J Med. 2007. PMID: 17506237 Review.
-
Does levodopa slow or hasten the rate of progression of Parkinson's disease?J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. doi: 10.1007/s00415-005-4008-5. J Neurol. 2005. PMID: 16222436 Review.
Cited by
-
The PM20D1-NADA pathway protects against Parkinson's disease.Cell Death Differ. 2024 Nov;31(11):1545-1560. doi: 10.1038/s41418-024-01356-9. Epub 2024 Aug 22. Cell Death Differ. 2024. PMID: 39174646
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical